Drug Store News4h
Celltrion receives FDA nod for Prolia, Xgeva biosimilars
Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...
Pharmabiz7h
US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva
US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...
The Pharma Letter8h
Russian trade groups call on govt to postpone discriminatory procurement rules
Leading pharmaceutical associations in Russia have called on the government to postpone the introduction of new procurement ...
Renal & Urology News20h
Denosumab Biosimilar Stoboclo, Osenvelt Get FDA Approval
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Hosted on MSN20h
Compounders Sue FDA; Young Women in Perimenopause; More Osteoporosis Biosimilars
A significant number of women ages 30 to 45 said they experience perimenopause-related symptoms, according to a study with 4,432 U.S. participants. (npj Women's Health) The CDC will stop processing ...
Managed Healthcare Executive21h
FDA Approves Prolia and Xgeva Biosimilars, Stoboclo and Osenvelt
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.